---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006118"
form_type: "8-K"
ticker: "ATAI"
cik: "0002081043"
company_name: "AtaiBeckley Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:51:20.446083+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO

## Summary
- Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
- Faerm receives $525k base salary, 40% target bonus, option for 1.275M shares, 285k RSUs (4-yr vest), and $85k sign-on bonus.
- Severance: 0.75x salary for 9 months; change-in-control: lump sum salary+target bonus plus accelerated equity vesting.
- Faerm previously CFO at Viracta Therapeutics, interim CFO at Harpoon Therapeutics, and CFO at Artiva Biotherapeutics.
- CEO cites Faerm's experience as BPL-003 nears Phase 3 and other clinical-stage programs advance.

## SEC filing metadata
- accession: 0001140361-26-006118
- form_type: 8-K
- ticker: ATAI
- cik: 0002081043
- company_name: AtaiBeckley Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2081043/000114036126006118/0001140361-26-006118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2081043/000114036126006118/ef20066047_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006118
- JSON: https://secwatch.observer/filing/0001140361-26-006118.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.